Jason Shafrin of FTI Consulting’s Center for Healthcare Economics and Policy published a new commentary in The Evidence Base titled “Perspectives from the Healthcare Economist: CMS Doesn’t Consider QALYs – What’s a Health Economist To Do?.”
“With CMS restricted from using from using quality-adjusted life years (QALYs) in Medicare drug price negotiations, health economists face a pressing question: what alternative measures can capture treatment value without discrimination? In his latest Guest Column, Dr. Shafrin explores emerging approaches and weighs their strengths and limitations.”
Key Contacts